GSK's Shingrix supply recovers thanks to drop in vaccinations, uninterrupted production

GSK's Shingrix supply recovers thanks to drop in vaccinations, uninterrupted production

Source: 
Fierce Pharma
snippet: 

GlaxoSmithKline’s shingles vaccine Shingrix shot out of the gate after its 2017 launch and performed so well that the drugmaker eventually ran into supply shortages due to higher-than-expected demand.

More recently, though, the COVID-19 pandemic put the brake on routine healthcare visits for most Americans. That’s led to a drop-off in vaccinations, which gave GSK some time to catch up on production. The company has produced “without interruption” during the pandemic, a spokesman said.